• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Low Dose Aspirin and Breast Cancer Prevention – Results from the CTS Cohort

image_pdfFavoriteLoadingFavorite

Purpose

Low-dose (81 mg) aspirin is recommended by USPSTF to reduce cardiovascular disease and colorectal cancer. As previous studies were inconclusive on the role of aspirin in the prevention of breast cancer, the aim of this study by Clarke et al. (Breast Cancer Res, 2017) was to determine whether hormone receptor subtypes (HR) and Her-2/neu receptor (HER2) status may be responsible for the variability in previous studies.

Methods

Observational Longitudinal Cohort: This study assessed data collected over several years from the California Teachers Study cohort. The cohort began in 1995-1996 and initially included 133,479 women, followed with baseline and ongoing annual questionnaires on family history and other cancer risk factors. The 2005-2006 questionnaire incorporated use of aspirin and other pain medications. In addition, the above data was linked to the California Cancer Registry and Office of Statewide Health Planning and Development which provides information on hospital services.

Results

Key findings include:

  • Overall, current use of at least three tablets a week of any NSAID was not associated with breast cancer
  • 3 or more tablets of low-dose aspirin per week was associated with a reduction in breast cancer, with a hazard ratio of 0.84 (95% CI 0.72-0.98)
    • The reduction in breast cancer was only observed in the case of positive HR/ HER2 negative status, with a hazard ratio of 0.80 (95% CI 0.66-0.96)
  • Timing and Frequency: 3 – 6 tablets of low-dose aspirin per week was further associated with breast cancer reduction compared to women not taking any NSAIDs during the past 3 years, with a hazard ratio of 0.72 (95% CI 0.54-0.96)
    • Similarly, this inverse association held for the HR positive/ HER negative status subtypes
  • Of note, the aspirin effect was seen with low-dose and not regular dose aspirin (325 mg)

Summary

  • This study demonstrates a 20% risk reduction for HR positive/Her2-negative breast cancer when low dose aspirin was used at least 3 times/week
  • Regular use, rather than sporadic use for pain may be a key factor in breast cancer reduction
  • Strengths of study:
    • Complete and accurate prospective data collection
  • Limitations of study:
    • Other possible confounders that were not obtained in the questionnaires (e.g. perhaps regular aspirin takers exercise more)
    • Observational and not interventional – questionnaires are ‘snapshots’ in time
    • Population used for this study may not mirror general population (e.g. educational status)

Learn More – Primary Sources

Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

USPSTF Guidance: When to Use Medication to Reduce Breast Cancer Risk
Atypical Hyperplasia of the Breast: Follow up and Management
Office Evaluation of Breast Disorders

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site